SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Status:
Recruiting
Trial end date:
2022-04-05
Target enrollment:
Participant gender:
Summary
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose
expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and
pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas.